Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV)

76 filings reported holding ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q2 2025.
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17.8M shares of 31.3M outstanding shares and own 56.87% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.34M shares), Sands Capital Alternatives, LLC (2.12M shares), CITADEL ADVISORS LLC (1.9M shares), WELLINGTON MANAGEMENT GROUP LLP (888K shares), VANGUARD GROUP INC (593K shares), RENAISSANCE TECHNOLOGIES LLC (509K shares), BlackRock, Inc. (408K shares), ACORN CAPITAL ADVISORS, LLC (405K shares), JACOBS LEVY EQUITY MANAGEMENT, INC (382K shares), and JANE STREET GROUP, LLC (312K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.